Lanfear, David E.

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., et al. (2021) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiomyopathy and Myosin Studies

Cited by 656

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 424

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

Spertus, J. A., Birmingham, M. C., Nassif, M., Damaraju, C. V., Abbate, A., Butler, J., Lanfear, D. E., Lingvay, I., Kosiborod, M. N., & Januzzi, J. L. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 245

Effect of “energy drink” consumption on hemodynamic and electrocardiographic parameters in healthy young adults

Steinke, L., Lanfear, D. E., Dhanapal, V., & Kalus, J. S. (2009) · Annals of Pharmacotherapy

Coffee research and impactsBlood Pressure and Hypertension Studies

Cited by 139

Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project

Shafiq, A., Brawner, C. A., Aldred, H. A., Lewis, B., Williams, C. T., Tita, C., Schairer, J. R., Ehrman, J. K., Velez, M., Selektor, Y., et al. (2016) · American Heart Journal

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 102